Literature DB >> 16006777

Parathyroid hormone-related protein and serum calcium in patients with renal cell carcinoma.

Karin Papworth1, Kjell Grankvist, Borje Ljungberg, Torgny Rasmuson.   

Abstract

OBJECTIVE: To evaluate serum parathyroid hormone-related protein (PTHrP) in relation to serum calcium and clinical outcome of patients with renal cell carcinoma.
METHODS: Sera from 243 patients with renal cell carcinoma were collected prior to therapy. Serum PTHrP was analyzed using an immunoradiometric assay. Tumour stage, nuclear grade, corrected serum calcium, and survival were assessed.
RESULTS: Serum PTHrP was detectable in 37/243 sera (15%) and hypercalcaemia (> or =2.60 mmol/l) in 32/220 (15%). A positive correlation between serum PTHrP and serum calcium was found (r = 0.326; p < 0.01). Following subdivision of the material, based on storage time, the frequency of detectable serum PTHrP seemed to decrease with time. Serum calcium, but not serum PTHrP, was correlated to tumour stage (p < 0.001). Survival was similar for patients with detectable and undetectable PTHrP, but those with hypercalcaemia had a significantly shorter survival time compared to those with normal serum calcium (p < 0.001). A multivariate analysis showed that tumour stage and serum calcium were independent prognostic factors, but not grade or PTHrP.
CONCLUSIONS: A positive relation of serum PTHrP to serum calcium was demonstrated in patients with renal cell carcinoma. Hypercalcaemia but not serum PTHrP predicted a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006777     DOI: 10.1159/000086953

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

Review 1.  Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature.

Authors:  Halit Karaca; Ayhan Lale; Mustafa Dikilitas; Metin Ozkan; Ozlem Er
Journal:  Med Oncol       Date:  2009-10-15       Impact factor: 3.064

2.  Hypercalcemia of malignancy with simultaneous elevation in serum parathyroid hormone--related peptide and 1,25-dihydroxyvitamin D in a patient with metastatic renal cell carcinoma.

Authors:  Sarika B Shivnani; John M Shelton; James A Richardson; Naim M Maalouf
Journal:  Endocr Pract       Date:  2009-04       Impact factor: 3.443

Review 3.  Renal cell carcinoma presenting with paraneoplastic hypercalcemic coma: a case report and review of the literature.

Authors:  Kara Pepper; Uraporn Jaowattana; Michael D Starsiak; Raghuueer Halkar; Kelly Hornaman; Wenli Wang; Priya Dayamani; Vin Tangpricha
Journal:  J Gen Intern Med       Date:  2007-04-19       Impact factor: 5.128

4.  Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma.

Authors:  Shuhei Kamada; Takeshi Namekawa; Kazuhiro Ikeda; Takashi Suzuki; Makoto Kagawa; Hideki Takeshita; Akihiro Yano; Koji Okamoto; Tomohiko Ichikawa; Kuniko Horie-Inoue; Satoru Kawakami; Satoshi Inoue
Journal:  Oncogene       Date:  2021-05-10       Impact factor: 9.867

5.  Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas.

Authors:  Masahiro Yao; Takayuki Murakami; Koichi Shioi; Nobuhiko Mizuno; Hiroki Ito; Keiichi Kondo; Hisashi Hasumi; Futoshi Sano; Kazuhide Makiyama; Noboru Nakaigawa; Takeshi Kishida; Yoji Nagashima; Shoji Yamanaka; Yoshinobu Kubota
Journal:  Cancer Med       Date:  2014-05-26       Impact factor: 4.452

6.  Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.

Authors:  Yoshiaki Kawano; Wataru Takahashi; Masatoshi Eto; Tomomi Kamba; Hideaki Miyake; Masato Fujisawa; Takao Kamai; Hirotsugu Uemura; Taiji Tsukamoto; Haruhito Azuma; Akio Matsubara; Kazuo Nishimura; Tsuyoshi Nakamura; Osamu Ogawa; Seiji Naito
Journal:  Cancer Sci       Date:  2016-06-14       Impact factor: 6.716

7.  Serum Calcium Levels Before Antitumour Therapy Predict Clinical Outcomes in Patients with Nasopharyngeal Carcinoma.

Authors:  Sheng-Yan Huang; Yang Chen; Xi-Rong Tan; Sha Gong; Xiao-Jing Yang; Qing-Mei He; Shi-Wei He; Na Liu; Ying-Qing Li
Journal:  Onco Targets Ther       Date:  2020-12-23       Impact factor: 4.147

8.  Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma.

Authors:  Shuhei Kamada; Kazuhiro Ikeda; Takashi Suzuki; Wataru Sato; Sachi Kitayama; Satoru Kawakami; Tomohiko Ichikawa; Kuniko Horie; Satoshi Inoue
Journal:  Front Oncol       Date:  2021-11-03       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.